Cardioprotective effect of pretreatment with β-glucan in coronary artery bypass grafting

Scandinavian Cardiovascular Journal

Volumn 40, Issue 5, 2006, Pages 298-304

  Aarsæther, Erling ^a   Rydningen, Mona ^a   Einar Engstad, Rolf ^b   Busund, Rolf ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b Biotec Pharmacon ASA   (Norway)

Author keywords

Cardiopulmonary bypass; Coronary artery bypass grafting; Ischemia reperfusion; Myocardial protection

Indexed keywords

ACUTE PHASE PROTEIN; BETA 1,3 GLUCAN; BETA 1,6 GLUCAN; BETA GLUCAN; C REACTIVE PROTEIN; CREATINE KINASE MB; CYTOKINE; HEART ENZYME; IMMUTOL; INTERLEUKIN 6; INTERLEUKIN 8; TROPONIN T;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOLOGICAL PARAMETERS; HUMAN; INFLAMMATION; LOW DRUG DOSE; MALE; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPERFUSION INJURY;

AGED; BETA-GLUCANS; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; FEMALE; HEART INJURIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PERIOPERATIVE CARE; TREATMENT OUTCOME;

EID: 33749417405     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430600868567     Document Type: Article

References (16)

1. Williams, DL and Browder, IW and Di Luzio, NR. (1983) Immunotherapeutic modification of Escherichia coli-induced experimental peritonitis and bacteremia by glucan Surgery, 93, pp. 448-54.
2. Seljelid, R and Rasmussen, LT and Larm, O and Hoffman, J. (1987) The protective effect of beta 1-3D-glucan derivatized plastic beads against Escherichia coli infection in mice Scand J Immunol, 25, pp. 55-60.
3. Dellinger, EP and Babineau, TJ and Bleicher, P and Kaiser, AB and Seibert, GB and Postier, RG and (1999) Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations Arch Surg, 134, pp. 977-83.
4. Rasmussen, LT and Fandrem, J and Seljelid, R. (1990) Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta-1,3-D-polyglucose derivatives. II. Interleukin 1, tumour necrosis factor, prostaglandin E2, and leukotriene B4 Scand J Immunol, 32, pp. 333-40.
5. Li, C and Ha, T and Kelley, J and Gao, X and Qiu, Y and Kao, RL and (2004) Modulating toll-like receptor mediated signaling by (1->3)-beta-D-glucan rapidly induces cardioprotection Cardiovasc Res, 61, pp. 538-47.
6. Valen, G and Paulsson, G and Vaage, J. (2001) Induction of inflammatory mediators during reperfusion of the human heart Ann Thorac Surg, 71, pp. 226-32.
7. Sharma, M and Ganguly, NK and Chaturvedi, G and Thingnam, SK and Majumdar, S and Suri, RK. (2003) Release of pro-inflammatory mediators during myocardial ischemia/reperfusion in coronary artery bypass graft surgery Mol Cell Biochem, 247, pp. 23-30.
8. Rao, V and Ivanov, J and Weisel, RD and Ikonomidis, JS and Christakis, GT and David, TE. (1996) Predictors of low cardiac output syndrome after coronary artery bypass J Thorac Cardiovasc Surg, 112, pp. 38-51.
9. Nicolosi, R and Bell, SJ and Bistrian, BR and Greenberg, I and Forse, RA and Blackburn, GL. (1999) Plasma lipid changes after supplementation with beta-glucan fiber from yeast Am J Clin Nutr, 70, pp. 208-12.
10. Rice, PJ and Adams, EL and Ozment-Skelton, T and Gonzalez, AJ and Goldman, MP and Lockhart, BE and (2005) Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge J Pharmacol Exp Ther, 314, pp. 1079-86.
11. Babineau, TJ and Marcello, P and Swails, W and Kenler, A and Bistrian, B and Forse, RA. (1994) Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients Ann Surg, 220, pp. 601-9.
12. Li, C and Browder, W and Kao, RL. (1999) Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart Am J Physiol, 276, pp. H543-H552.
13. Onai, Y and Suzuki, J and Kakuta, T and Maejima, Y and Haraguchi, G and Fukasawa, H and (2004) Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury Cardiovasc Res, 63, pp. 51-9.
14. Wayman, NS and Hattori, Y and McDonald, MC and Mota-Filipe, H and Cuzzocrea, S and Pisano, B and (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J, 16, pp. 1027-40.
15. Zingarelli, B and Hake, PW and Denenberg, A and Wong, HR. (2002) Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury Shock, 17, pp. 127-34.
16. Pye, J and Ardeshirpour, F and McCain, A and Bellinger, DA and Merricks, E and Adams, J and (2003) Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury Am J Physiol Heart Circ Physiol, 284, pp. H919-H926.